A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis
NCT00352755 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18
Last updated 2016-12-13
Summary
This study prospectively evaluates a multidisciplinary approach to patients with intraperitoneal carcinomatosis at Washington University. Patients with peritoneal carcinomatosis or pseudomyxoma peritonei will undergo debulking surgery with peritonectomy and placement of adhesive barrier film followed by repeated delayed intraperitoneal chemotherapy with 5FU with systemic oxaliplatin-based chemotherapy on a biweekly schedule. A retrospective review of patients treated in a similar manner at our institution showed good tolerance and efficacy. This formal Phase II study is planned to determine the safety, toxicities and survival of patients with peritoneal carcinomatosis and pseudomyxoma peritonei treated with this regimen.
Conditions
- Peritoneal Neoplasms
Interventions
- PROCEDURE
-
Surgical debulking with peritonectomy
- DRUG
-
Intraperitoneal 5FU
- DRUG
Sponsors & Collaborators
-
Washington University School of Medicine
lead OTHER
Principal Investigators
-
James Fleshman, M.D. · Washington University School of Medicine
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-05-31
- Primary Completion
- 2009-04-30
- Completion
- 2009-04-30
Countries
- United States
Study Locations
More Related Trials
-
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02713386 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02050009 ·Status: WITHDRAWN ·Phase: PHASE1
-
Study of Efficacy and Safety of Laparoscopic Intra-abdominal Chemotherapy (PIPAC) Performed in Patients With Peritoneal Carcinomatosis From Colorectal, Ovarian, Gastric Cancer and Primary Peritoneal Tumors
NCT02604784 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04387227 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02853318 ·Status: COMPLETED ·Phase: PHASE2
-
Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00079430 ·Status: COMPLETED ·Phase: PHASE1
-
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT01167712 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
NCT00588237 ·Status: COMPLETED ·Phase: PHASE2
-
Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00617773 ·Status: COMPLETED ·Phase: PHASE2
-
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT02627443 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
NCT00954174 ·Status: UNKNOWN ·Phase: PHASE3
-
Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma
NCT02217956 ·Status: COMPLETED ·Phase: PHASE1
-
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT01175343 ·Status: COMPLETED ·Phase: PHASE2
-
Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
NCT00060359 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer
NCT01281514 ·Status: COMPLETED ·Phase: PHASE1
-
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer
NCT00108745 ·Status: UNKNOWN ·Phase: PHASE3
-
Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT02520154 ·Status: COMPLETED ·Phase: PHASE2
-
Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT01767675 ·Status: COMPLETED ·Phase: PHASE2
-
Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer
NCT01137071 ·Status: TERMINATED ·Phase: PHASE2
-
Hyperthermic Intraperitoneal Oxaliplatin for Peritoneal Malignancies
NCT00625092 ·Status: COMPLETED ·Phase: PHASE1
-
Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer
NCT02125513 ·Status: UNKNOWN ·Phase: PHASE2
-
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
NCT04919629 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers
NCT00698451 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
NCT00031954 ·Status: COMPLETED ·Phase: PHASE2
-
PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer
NCT00055705 ·Status: COMPLETED ·Phase: PHASE1